top of page
how_chondroplus_works.png
how_chondroplus_works_2.png

Chondroplus – Mechanism of Action

cp_1.png

Chondroplus has been developed and manufactured based on scientific data.

  • The product’s primary purpose is to stimulate endogenous hyaluronic acid (HA) production by type B synovial cells.

  • These cells are activated via HA receptors on their surface. Once stimulated, they release endogenous HA into the synovial space.

  • Endogenously produced HA initially has a very high molecular weight (~40 million Daltons).

  • Over time, this HA undergoes physiological degradation (physical and chemical breakdown), resulting in molecules with a molecular weight of 2–4 million Daltons.

  • These medium-sized HA molecules also bind to synovial cell receptors, re-stimulating type B synoviocytes and ensuring a continuous cycle of HA production.

In inflammatory diseases such as osteoarthritis, the natural balance of the joint environment is disrupted. This occurs due to excessive degradation of endogenous hyaluronan (HA) and insufficient stimulation of type B synoviocytes. To break this vicious cycle, the body requires supplementation with exogenous hyaluronan (HA).

Scientific evidence shows that the selection of HA for synovial fluid replacement must be based on two critical factors:

  1. Molecular Weight – The optimal range for stimulating type B synoviocytes is 2–4 million daltons.

  2. Molecular Structure – HA must maintain a linear physical configuration to achieve maximal receptor activation.

In line with this data, Chondroplus is formulated with hyaluronic acid of 3.8 million daltons, ensuring both effective stimulation of type B cells and restoration of synovial fluid balance.

Since increasing both physical and chemical stability is scientifically proven to be essential—alongside selecting the correct molecular weight—Chondroplus incorporates microwave-stabilised hyaluronic acid (HA).
The HA component of Chondroplus is based on Reganemed’s patented Long-Acting Hyaluronic Acid (LAHA) technology, which ensures prolonged residence time in the joint and sustained therapeutic effect.

cp_2.png
cp_3.png

  • Increasing the dose of hyaluronic acid (HA) does not necessarily enhance clinical outcomes. A fundamental principle of pharmacology is that the optimal dose is not the highest dose, but the most effective one.

  • Experimental data demonstrate that low concentrations of HA significantly stimulate the metabolic activity of chondrocytes, providing long-term clinical benefits. Chondrocytes respond in a dose-dependent manner, regulated by a negative feedback mechanism via CD44 receptors:

  • At low HA concentrations, chondrocyte proliferation and extracellular matrix (ECM) synthesis are enhanced.

  • At high HA concentrations, these processes decline, and excessive HA exposure can even induce chondrocyte apoptosis.

  • The critical threshold has been identified at 20 mg/ml: doses above this level no longer provide benefit and may trigger adverse cellular effects.

Collagen Tripeptide (CTP) and Cartilage Health

cp_4.png

  • Small collagen-derived peptides, such as CTP, have been shown to exhibit growth factor-like activities. Specifically, CTP stimulates chondrocytes to increase type II collagen gene expression.

  • Intra-articular administration of CTP has multiple protective and regenerative effects on cartilage:

    • Suppresses cartilage matrix loss

    • Prevents proteoglycan degradation

    • Promotes new extracellular matrix (ECM) synthesis

  • CTP combined with hyaluronic acid (HA) further enhances tissue regeneration by:

    • Promoting fibroblast proliferation

    • Increasing collagen biosynthesis

    • Stimulating growth factor production

  • Outcome: Accelerated regeneration of cartilage and connective tissue

  • Mechanisms behind CTP’s beneficial effects on cartilage:

    1. Anabolic effect: Enhancement of cartilage matrix synthesis

    2. Anti-catabolic effect: Inhibition of cartilage degeneration

Synthetic Collagen Tripeptide in Chondroplus

cp_5.png

  • Chondroplus incorporates synthetic collagen tripeptides to eliminate risks of animal contamination and allergic reactions.

  • Collagen Tripeptides (CTP) are highly purified, non-antigenic peptides with direct biological activity. By stimulating type II collagen synthesis, enhancing extracellular matrix (ECM) production, and protecting cartilage from degradation, CTP provides a dual mechanism of protection and regeneration, making it an effective approach for osteoarthritis and other cartilage-related conditions.

bottom of page